DNA methylation clocks estimate biological age and may become trial tools, but they are not a substitute for health outcomes.
Page status
- Needs citations for clock families
- Needs clearer consumer-testing caveats
Key takeaways
- Clock age can move without proving that healthspan improved.
- Different clocks answer different questions: chronological prediction, mortality risk, pace of aging, or tissue state.
- The strongest use case is faster feedback inside trials, not direct consumer ranking.
Mechanism
Epigenetic clocks use methylation patterns across many genomic sites to estimate age-related biological state. They are statistical instruments, not literal clocks inside the cell.
A clock can be useful even when its mechanism is partly opaque, but interpretation needs validation against disease risk, function, and survival.
Limitations
A supplement, diet, drug, or training block that improves a clock score has not automatically extended life. The score may be sensitive to immune shifts, cell composition, or temporary stress responses.
For a wiki reader, clocks are best treated as dashboard instruments. They can guide questions, but they should not overrule clinical markers or lived function.
Watchlist
- Tissue-specific clocks
- Clinical endpoint validation
- Consumer testing drift
- Trial surrogate rules
References
- Multi-tissue methylation clock. Horvath, Genome Biology, 2013. Foundational DNA methylation age model across tissues and cell types.
- Mammalian methylation clocks. Nature Aging, 2023. Use for cross-species context and interpretation limits.
What links here
- Biohacking Risk LedgerSelf-experimentation should be judged by reversibility, measurement quality, downside planning, and evidence strength.
- Cellular ReprogrammingPartial reprogramming aims to restore youthful cell function without erasing identity or triggering uncontrolled growth.
- Longevity Pharma PipelineAging-targeted pharma is moving from supplement claims toward indication-led trials, combination logic, and prevention endpoints.